Menu Search
Equities

Pro Medicus Ltd

PME:ASX

Pro Medicus Ltd

Actions
Health CareHealth Care Providers
  • Price (AUD)171.35
  • Today's Change1.51 / 0.89%
  • Shares traded280.00k
  • 1 Year change+140.32%
  • Beta1.0796
Data delayed at least 20 minutes, as of Sep 19 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 13-Sep-24
Select bar for recommendation details.
Recommendations13-Sep-24
Buy0
Outperform3
Hold9
Sell0
Strong Sell1

Share price forecast in AUD

The 13 analysts offering 12 month price targets for Pro Medicus Limited have a median target of 140.00, with a high estimate of 160.00 and a low estimate of 57.86. The median estimate represents a -18.30% decrease from the last price of 171.35.
High-6.6%160.00
Med-18.3%140.00
Low-66.2%57.86

Dividends in AUD

In 2024, Pro Medicus Ltd reported a dividend of 0.40 AUD, which represents a 33.33% increase over last year. The 14 analysts covering the company expect dividends of 0.52 AUD for the upcoming fiscal year, an increase of 30.00%.
Div growth (TTM)33.33%
More ▼

Earnings history & estimates in AUD

Pro Medicus Limited reported annual 2024 earnings of 0.791 per share on Aug 13, 2024.
Average growth rate+37.60%
More ▼

Revenue history & estimates in AUD

Pro Medicus Limited had revenues for the full year 2024 of 166.33m. This was 33.17% above the prior year's results.
Average growth rate+30.99%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.